US 8946241B2
· Goldstein
· 2015
[cited by applicant]
WO 2012158764A1
· 2012
[cited by applicant]
WO 2022081512A1
· 2022
[cited by applicant]
Ahmed, A., et al., “Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal,” British Journal of Dermatology, vol. 178, pp.…
[cited by applicant]
Bennett, J.M., et al., “Inflammation—Nature's Way to Efficiently Respond to All Types of Challenges: Implications for Understanding and Managing “the Epidemic” of Chronic Diseases,” Frontiers in Medicine (Lausanne), vol…
[cited by applicant]
Bieber, T., “Atopic dermatitis,” Annals of Dermatology, vol. 22, No. 2, pp. 125-137 (2010).
[cited by applicant]
Bieber, T., et al., “Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?,” Journal of Allergy Clinical Immunology, vol. 139, No. 4S, pp. S58-S64 (2017).
[cited by applicant]
Bissonnette, R., et al., “Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial,” Journal of Allergy and Clinical Immunology, vol. 144, No. 5, pp. 1274-1289 (2019).
[cited by applicant]
Bizikova, P., et al., “Cloning and establishment of canine desmocollin-1 as a major autoantigen in canine pemphigus foliaceus,” Veterinary Immunology and Immunopathology, vol. 149, pp. 197-207 (2012).
[cited by applicant]
Bizikova, P., et al., “Serum autoantibody profiles of IgA, IgE, and IgM in canine pemphigus foliaceus,” Veterinary Dermatology, vol. 25, No. 5, p. 471 (2014).
[cited by applicant]
Boguniewicz, M., et al, “Atopic dermatitis: a disease of altered skin barrier and immune dysregulation,” Immunology Review, vol. 242, No. 1, pp. 233-246 (2011).
[cited by applicant]
Boguniewicz, M., et al., “Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies,” Journal of Allergy Clinical Immunology Pract…
[cited by applicant]
Byrd, J.C., et al., “Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia,” New England Journal of Medicine, vol. 369, pp. 32-42 (2013).
[cited by applicant]
Caira, M., “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, vol. 198, pp. 163-208 (1998).
[cited by applicant]
Capen, C.C., “Mechanisms of chemical injury of the thyroid gland,” Progress in Clinical and Biological Research, vol. 387, pp. 173-191 (1994).
[cited by applicant]
Chang, B.Y., et al., “The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells,” Arthritis Research & Therapy, vol. 13, p. R115 (2011).
[cited by applicant]
Crofford, L.J., et al., “The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy,” Expert Review of Clinical Immunology, vol. 12, No. 7, pp. 763-773 (2016).
[cited by applicant]
Curran, P.G., et al., “The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland,” Endocrinology, vol. 12, No. 2, pp. 135-150 (1991).
[cited by applicant]
DiPaolo, J.A., et al., “Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis,” Nature Chemical Biology, vol. 7, pp. 41-50 (2011).
[cited by applicant]
Eichenfield, L.F., et al., “Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies,” Journal of the American Academy of Dermatology, v…
[cited by applicant]
Futatani, T., et al., “Brutons tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females,” British Journal of Hematology, vol. 114, No. 1, p…
[cited by applicant]
Goodale, E.C., et al., “Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus,” Veterinary Dermatology, vol. 31, No. 4, p. 291 (2020).
[cited by applicant]
Hanifin, J.M., et al., “Diagnostic features of atopic dermatitis,” Acta Dermato-Venereologica Supplement (Stockholm), vol. 92, pp. 44-47 (1980).
[cited by applicant]
Herter, J.M., et al., “PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling,” British Journal of Pharmacology, vol. 175, No. 3, pp. 429-439 …
[cited by applicant]
Honigberg, L.A., et al., “The Bruton tyrosine kinase inhibitor PCI-32765 blocks B cell activation and is efficacious in models of autoimmune disease and B cell malignancy,” PNAS, vol. 107, pp. 13075-13080 (2010).
[cited by applicant]
Hutcheson, J., et al., “Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and endorgan disease in murine lupus,” Arthritis Research & Therapy, vol. 14, p. R243 (2012).
[cited by applicant]
Ihrke, P.J., et al., “Pemphigus foliaceus in dogs: a review of 37 cases,” Journal of the American Veterinary Medical Association, vol. 186, No. 1, pp. 59-66 (1985).
[cited by applicant]
International Preliminary Report on Patentability issued for PCT/US2021/012515 on Jul. 21, 2022 (8 pages).
[cited by applicant]
International Search Report for PCT/US2021/012515 mailed Mar. 12, 2021 (14 pages).
[cited by applicant]
Irwin, S., “Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse,” Psychopharmacologia, vol. 13, No. 3, pp. 222-257 (1968).
[cited by applicant]
Kim, K.H., et al., “Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis,” Bioorganic & Medicinal Chemistry Letters, vol. 21, No. 21, pp. 6258-6263 (2011).
[cited by applicant]
Lebakken, C.S., et al., “Development and application of a broad-coverage, TR-FRET-based kinase binding assay platform,” Journal of Biomolecular Screening, vol. 14, pp. 924-935 (2009).
[cited by applicant]
Maronpot, R.R., et al., “Hepatic Enzyme Induction: Histopathology,” Toxicologic Pathology, vol. 38, No. 5, pp. 776-795 (2010).
[cited by applicant]
Mohamed, A.J., et al., “Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain,” Immunology Review, vol. 228, pp. 58-73 (2009).
[cited by applicant]
Oliveira, S., et al., “Neutrophil migration in infection and wound repair: going forward in reverse,” Nature Reviews Immunology, vol. 16, No. 6, pp. 378-391 (2016).
[cited by applicant]
Outerbridge, C., et al., A New Treatment for Autoimmune Blistering Diseases: Efficacy of the Bruton's Tyrosine Kinase (BTK) Inhibitor PRN473 in Canine Pemphigus Foliaceus, Poster #3530, 74th Annual Meeting, American Aca…
[cited by applicant]
Patel, K.R., et al., “Association between atopic dermatitis, depression, and suicidal ideation: A systematic review and meta-analysis,” Journal of the American Academy of Dermatology, vol. 80, No. 2, pp. 402-410 (2019).
[cited by applicant]
Petersen, L.J., et al., “Histamine is released in the wheal but not the flare following challenge of human skin in vivo: a microdialysis study,” Clinical & Experimental Allergy, vol. 27, No. 3, pp. 284-329 (1997).
[cited by applicant]
Press Release, “Sanofi to acquire Principia Biopharma,” Aug. 17, 2020.
[cited by applicant]
Rip, J., et al., “The role of Bruton's Tyrosine Kinase in immune cell signaling and systemic autoimmunity,” Critical Reviews in Immunology, vol. 38, No. 1, pp. 17-62 (2018).
[cited by applicant]
Sideras, P., et al., “Molecular and cellular aspects of X-linked agammaglobulinemia,” Advanced Immunology, vol. 59, pp. 135-223 (1995).
[cited by applicant]
Silverberg, J.I., “Public Health Burden and Epidemiology of Atopic Dermatitis,” Dermatologic Clinics, vol. 35, No. 3, pp. 283-289 (2017).
[cited by applicant]
Silverberg, J.I., “Selected comorbidities of atopic dermatitis: Atopy, neuropsychiatric, and musculoskeletal disorders,” Clinical Dermatology, vol. 35, No. 4, pp. 360-366 (2017).
[cited by applicant]
Silverberg, J.I., et al., “Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study,” Annals of Allergy, Asthma & Immunology, vol. 121, No. 3, pp. 340-347 (2018).
[cited by applicant]
Spiewak, R., “Inter- and intra-individual variability of skin reactivity to histamine at prick-testing,” Dermatology Online Journal, vol. 1, No. 1 (1995).
[cited by applicant]
Trial Registration No. ACTRN12613000951752, “A Phase I, Randomised, Double-Blind, Placebo-Controlled, Ascending Single- and Repeat-Dose Study of the Safety, Tolerability and Pharmacokinetics of Orally Administered PRN47…
[cited by applicant]
Trial Registration No. ACTRN12620000264298, “A Healthy Volunteer Study Evaluating the Tolerability and Pharmacokinetics of PRN473 Topical,” Australian New Zealand Clinical Trials Registry, Feb. 28, 2020.
[cited by applicant]
Trial Registration No. ACTRN12620000693921, “An interventional study to evaluate the effect and safety of PRN473 topical on skin reactions of otherwise healthy participants with allergies to common allergens,” Australia…
[cited by applicant]
Volmering, S., et al., “The Neutrophil Btk Signalosome Regulates Integrin Activation during Sterile Inflammation,” Immunity, vol. 44, No. 1, pp. 73-87 (2016).
[cited by applicant]
Weidinger, S., et al., “Atopic dermatitis,” Nature Reviews Disease Primers, vol. 4, No. 1, p. 1 (2018).
[cited by applicant]
Werfel, T., et al., “Cellular and molecular immunologic mechanisms in patients with atopic dermatitis,” Journal of Allergy and Clinical Immunology, vol. 138, No. 2, pp. 336-349 (2016).
[cited by applicant]
Xu, D., et al. “RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents, ”Journal of Pharmacology and Experimental Therapeutics, vol. 341, pp. 90-103 (…
[cited by applicant]
Zane, L.T., et al., “Tolerability of crisaborole ointment for application on sensitive skin areas: A randomized, double-blind, vehicle-controlled study in healthy volunteers,” American Journal of Clinical Dermatology, v…
[cited by applicant]
Hirayama, N., “Handbook for organic compounds crystal preparation,” pp. 17-23, 37-40, 45-51, 57-65 (2008).
[cited by applicant]